Health

Nucleus Genomics Sparks Outrage with Controversial Embryo Selection Product: 'Absolutely Nauseating'

2025-06-06

Author: Ting

Controversial Beginnings of Nucleus Genomics

Founded in 2021 by the visionary 25-year-old Kian Sadeghi, Nucleus Genomics has always been a polarizing name in the world of genetic testing. Initially aimed at assessing disease risks, the startup has since escalated its controversial reputation with products that link genetics to complex characteristics, including intelligence.

Nucleus Embryo: The Game-Changer or a Moral Dilemma?

On Wednesday, the company ignited a firestorm of debate with the launch of its latest offering, Nucleus Embryo. Their bold marketing statement proclaimed: 'Every parent wants to give their children more than they had.' But what exactly does that mean in practice?

Nucleus Embryo claims to provide comprehensive testing for IVF embryos, not only assessing for well-known genetic disorders but also evaluating traits like sex, height, hair color, eye color, and even intelligence. Their promotional materials shockingly suggest that parents could select which embryos to implant based on these genetic 'desirables.'

The Science Behind Polygenic Scores: Promises or Pitfalls?

While genetic testing isn't new in assisted reproduction, Nucleus is venturing into murky waters by utilizing controversial polygenic scores. Unlike traditional gene testing that identifies specific high-risk conditions, these scores offer only probabilities of complex traits, without clear guidelines around their use.

The National Human Genome Research Institute warns that while polygenic scores can indicate risk levels, they do not determine absolute outcomes--a critical distinction that the public may not understand.

The Reaction: Horror and Skepticism

The announcement has sent shockwaves through social media, amassing over 4 million views and spawning a barrage of critical comments. Many users expressed disbelief and dread at the ethical implications of such testing. One venture capitalist articulated the shared sentiment perfectly: 'Honestly, the reality of this just makes me so nauseous.'

Previous Backlash and Financial Backing

Nucleus is no stranger to controversy. Earlier this year, the company raised $14 million in Series A financing amidst criticism over its previous product, Nucleus IQ, which aimed to gauge the genetic influence on intelligence—an idea many have dismissed as 'bad science'.

Despite the backlash, the startup has garnered support from high-profile backers, including Founders Fund and notable angel investors.

Navigating the Future of Genetic Testing

Interestingly, Nucleus isn’t conducting these embryo tests directly but instead collaborating with Genomic Prediction, which partners with IVF clinics. While some parents are curious about intelligence testing, Genomic Prediction claims it does not offer this service.

Kian Sadeghi defended the venture in a promotional video, reflecting on the historical stigma of IVF technology and asserting that genetic optimization is a natural next step in medical advancement—an assertion that will surely incite further debate.